Journal
BMC CANCER
Volume 16, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12885-016-2681-7
Keywords
Breast cancer; Stomatin; HER2; Tumor biomarkers
Categories
Funding
- National Science Council, Taiwan, Republic of China [NSC 99-2314-B-010-045, MOST 104-2320-B-010-043-MY3, MOST 105-2319-B010-001]
Ask authors/readers for more resources
Background: Human epidermal growth factor receptor-2 (HER2) is a transmembrane tyrosine kinase receptor that is overexpressed in 25 to 30 % of human breast cancers and is preferentially localized in lipid rafts. Stomatin is a membrane protein that is absent from the erythrocyte plasma membrane in patients with congenital stomatocytosis and is the major component of the lipid raft. Results: In a total of 68 clinical cases of HER2-positive breast cancer, the absence of stomatin expression was associated with a decreased 5-year survival (65 % vs. 93 %, p = 0.005) by survival analysis. For stage I-III HER2-positive breast cancer, the absence of stomatin expression was associated with a decreased 5-year disease-free survival (57 % vs. 81 %, p = 0.016) and was an independent prognostic factor by multivariate analysis. Negative stomatin expression predicts distant metastases in a hazard ratio of 4.0 (95 % confidence interval from 1.3 to 12.5). Conclusions: These results may suggest that stomatin is a new prognostic indicator for HER2-positive breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available